Kymera Therapeutics Stock Fair Value – Analysts Give Kymera Therapeutics, an Average Rating of ‘Moderate Buy’
December 21, 2023
🌥️Trending News
Kymera Therapeutics ($NASDAQ:KYMR), Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, innovative therapies for hematologic and solid tumor diseases. The company is committed to developing therapies to address unmet medical needs for patients with cancer, autoimmune, and other serious conditions. Recently, analysts have given Kymera Therapeutics, Inc. an average rating of “Moderate Buy”. This rating is based on the company’s strong performance and potential for further growth. The analyst consensus suggests that Kymera Therapeutics, Inc. is poised to grow in the near future, offering investors potential capital gains on their investments. The analysts have noted the company’s ability to develop novel therapies for hematologic and solid tumor diseases as a key factor in their decision to give an average rating of “Moderate Buy”.
In addition, Kymera Therapeutics, Inc. has recently shown impressive results in clinical trials, which has further strengthened the analyst’s confidence in the company. This rating underscores the company’s potential for growth, and potential investors should consider the analysts’ opinion before deciding whether or not to invest in Kymera Therapeutics, Inc.
Share Price
The stock opened at $25.0 and closed at $24.5, which was 1.8% lower than the previous closing price of $25.0. This suggests that analysts remain optimistic about the company’s prospects in the near term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 46.85 | -167.46 | -357.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…
| Operations | Investing | Financing |
| -150.41 | 71.27 | 4.21 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 552.38 | 156.84 | 7.14 |
Key Ratios Snapshot
Some of the financial key ratios for Kymera Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.6% | – | -357.0% |
| FCF Margin | ROE | ROA |
| -370.7% | -25.2% | -18.9% |
Analysis – Kymera Therapeutics Stock Fair Value
GoodWhale recently analyzed the financials of KYMERA THERAPEUTICS and found that the fair value of its share is around $27.2. This was determined by using our proprietary Valuation Line, which accurately assesses the true value of a company’s stock. Interestingly, KYMERA THERAPEUTICS stock is currently trading at $24.5, which is a 9.9% discount to its true worth. This could be a great opportunity for potential investors to buy low and reap the rewards when the stock price matches its fair value. More…
Peers
The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.
– Abionyx Pharma ($LTS:0RAG)
Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.
– Prestige BioPharma Ltd ($KOSE:950210)
Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).
Summary
Analysts have provided a “Moderate Buy” rating for Kymera Therapeutics, Inc. indicating that it is a good stock to consider investing in. The stock has potential to generate returns in the short and long term. Kymera Therapeutics is focused on developing treatments for diseases that have limited therapeutic options. The company is leveraging its expertise in advanced drug discovery technologies to develop new medicines with the potential to address unmet medical needs. The company currently has a pipeline of multiple therapies in various stages of development, across multiple therapeutic areas.
Kymera has a strong and experienced leadership team and established partnerships with key industry players. The company also has a long record of successful collaborations and investments that have enabled it to accelerate its drug development programs. Given its potential, Kymera Therapeutics is an attractive stock to consider investing in, with the “Moderate Buy” rating from analysts providing further justification to invest.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
